Atreo Welcomes Jon Dole and Mark Paiz as New Board Members

New Board Appointees Bolster Atreo’s Seasoned Executive Team

SAN FRANCISCO, July 24, 2023 /PRNewswire/ — Atreo, Inc., a next-generation RTSM technology company, is thrilled to announce the appointment of two new distinguished board members, Jon Dole and Mark Paiz, who bring a wealth of industry experience to our organization. The decision was finalized during Atreo’s Annual Stockholder’s Meeting held on July 19, 2023.

Jon and Mark’s appointment to Atreo’s board fortifies the company’s strategic direction with extensive industry knowledge and exceptional accomplishments in the RTSM / IRT / Clinical Supplies domains.  Their addition to the board marks a pivotal moment in Atreo’s journey, further solidifying its position as a technology leader in RTSM space.

Jon and Mark’s deep expertise of our industry and scaling technology companies will surely bolster Atreo’s growth plans.

Jon Dole is a RTSM visionary and successful entrepreneur.  Jon has founded multiple RTSM companies and has been instrumental in driving Atreo’s innovation focus.  His strategic vision and deep understanding of the RTSM space will undoubtedly complement Atreo’s growth objectives.

Mark Paiz is a seasoned Life Sciences Technology executive and entrepreneur, bringing several decades of experience to Atreo, having held prominent leadership roles at both startups and Fortune 500 organizations.  His insights into scaling technology organizations and Clinical Supplies experience make him an invaluable asset to Atreo.

“We are thrilled to welcome Jon and Mark to Atreo’s Board of Directors. Their impressive track records and deep understanding of our industry will significantly enhance our ability to chart a successful course for the future,” said Ryan Harrison, CEO of Atreo.  “Both Mark and Jon have been actively providing their expertise and guidance since Atreo’s founding, demonstrating their dedication to our mission from day one.  Their commitment to the organization’s values and vision makes them an ideal fit to support Atreo’s continued growth.”

About Atreo:

Atreo is a modern RTSM company, comprised of experienced clinical technology experts, that has created the next generation of RTSM platform.  Atreo helps clinical teams to modernize the RTSM experience with unmatched agility and simplicity by leveraging advanced technology and testing practices. Atreo has solved all common RTSM challenges, offering numerous advantages, with a specific emphasis on:

Speed: 1 – 2 Week RTSM build from Kickoff to Launch
Collaborative RTSM Design: RTSM configured prior to Kickoff Meeting
Agility: System changes at no cost and unmatched quality

SOURCE Atreo, Inc.

Atreo’s v1.2 Release to be Presented at SCOPE 2023, February 7-8th in Orlando 


Atreo’s seasoned team of RTSM experts continues to set new standards in terms of what can be accomplished by leveraging modern technology.  Our new v1.2 release, featuring several refinements based on client feedback and internal expertise, will be showcased at SCOPE 2023 in Orlando next week.  This release builds upon our already robust Studio configuration tool, helping to further simplify our client engagements and offer control of your clinical supply strategies in ways uncommon of legacy RTSM providers.

Our commitment is to streamline the RTSM delivery process, provide a collaborative and unique system design experience, and always prioritize the knowledge and expertise of our Atreo’s RTSM experts as the cornerstone of our client relationships.  We are proud to say that our clients share this sentiment and can attest to the benefits of Atreo’s approach.

Atreo’s team of RTSM SMEs will be at Booth 334 at SCOPE, February 7th & 8th.  Please reach out to our Business Development Team to set up a demo of the latest advancements in RTSM technology:        

Excited to see you all in Orlando!

Ryan Harrison


Atreo PR Newswire Press Release

Atreo Secures $4M Funding Led by RTSM Veterans and SaaS Visionaries


Today marks an amazing milestone for Atreo.  I am excited to share closing of our 2nd fund raising round, providing the necessary capital to support our current and prospective clients and further advancements to our next generation RTSM platform.  Thank you to all investors who took part in this round, many of whom chose to reinvest in Atreo based on our progress to date and confidence in our team.    

To say I am proud of what we have accomplished over the past year is a huge understatement.  We have been so fortunate to align with driven, inquisitive, and collaborative Atreo team members who share our values and vision for what can be accomplished by leveraging new technology with an open mind.

Atreo’s commercial launch has been overwhelmingly well received.  Our initial client partners have recognized first-hand the many benefits of our approach, collaborative delivery, simplicity of our platform and the time saved in comparison to the industry norm.  We are truly grateful for their enthusiasm to embrace an emerging technology company. 

“Now that I have worked with Atreo, there is no reason to explore another RTSM provider.” 

Atreo’s 1st Client | Head of Clinical Operations  

Stay tuned for exciting updates in the weeks to come! 

Ryan Harrison

Atreo PR Newswire Press Release